Yesterday
There were a few of us yesterday that tried to calm the waters and discredit those who were screaming that we would lose our shares. I may have been harsher than some….I get that way sometimes when people mislead others. I hate the injustice and manipulation of it. I would like to thank chrisbaskett, uncxman, stakddek, retired investor, matrix, cosmiclifeform for standing with me and working the truth out a day ahead of the press release. Sincerely…thank you.
To the bashers, I hope that you all realize the weight of the PR of 4/5. This is the first PR of its kind for DNAP in that they will be creating / enhancing a drug and to the point will have exclusive rights to a drug that already has several patents. This appears to essentially give DNAP 8 patents from 0 because it is exclusive. There are those that state, “well, there is no time table”. This is true as far as we know; however, we are not privy to everything and PT-401 is already discovered. Plus, DNAP’s enhancements will come from tech that they already have. How much (blind) faith do you need to think that Harvard would agree to an exclusive deal that will not produce? Some perhaps…but not much. The PR is not a guarantee for revenue…this also is true, but it is the best news that DNAP has ever (IMHO) come out with. Look at the facts and not conjecture:
We have an exclusive deal with one of the most reputable medical organizations in the world.
We have essentially picked up the rights to several patents.
We are working on a drug that already has a billion dollar market in a lesser form.
Lastly, we are working on a drug that the FDA as already approved the core form and application for.
I wish the honest well and the misguided peace, enlightenment, and a clean pure soul before you pass.
Big, I love this stuff, Blue
_____________________
"Our EPO technology has significant promise as a more powerful and commercially successful application of Erythropoietin," stated BIDMC's Dr. Arthur J. Sytkowski, who holds patents related to the new "Super"-EPO. "We are pleased that DNAPrint has made a commitment to work with BIDMC in expanding the potential for this drug."
The human gene that produces EPO was cloned in 1985, and, in 1989, scientists at Amgen introduced to market a recombinant form under the trade name EPOGEN®, a drug that many credit for the rise of Amgen in the 1990s as one of the world's most successful biotechnology companies ever.
Patients undergoing certain therapies or with certain conditions are often rendered anemic, meaning their red blood cell count drops dramatically. Without adequate amounts of erythropoietin in the blood, red blood cells are not regenerated efficiently, and there are too few red blood cells to deliver oxygen sufficiently throughout the body. Erythropoietin has been approved by the U.S. Food and Drug Administration as a treatment for anemia associated with renal failure, cancer chemotherapy, zidovudine-treated HIV-infected patients and to reduce blood transfusion in surgery patients. Anemia leaves patients tired, often impairing their ability to work or perform even routine tasks and over the last decade, EPO has proven to improve quality of life and overall fitness of those patients.
In 1995, Dr. Sytkowski, Director for the Laboratory for Cell and Molecular Biology, Division of Hematology and Oncology at Beth Israel Deaconess, was awarded the first in a string of eight patents covering methods of producing and using recombinant protein multimers with increased biological activity. In these patents, which are subject of the exclusive DNAPrint license announced today, Dr. Sytkowski described a new dimer (double) form of EPO -- "Super"-EPO, that elicited a heartier, more predictable hematocrit (red blood cell count) response, constituting a significant improvement over existing EPO technology.
AI
